Efficacy and tolerability of oral budesonide in Japanese patients with active Crohn's disease: A multicentre, double-blind, randomized, parallel-group Phase II study

Journal of Crohn's and Colitis

Volumn 7, Issue 3, 2013, Pages 239-247

  Suzuki, Yasuo ^a   Motoya, Satoshi ^b   Takazoe, Masakazu ^c   Kosaka, Tadashi ^d   Date, Masataka ^e   Nii, Masahiro ^e   Hibi, Toshifumi ^f  

^a TOHO UNIVERSITY   (Japan)

^b Sapporo Kosei General Hospital   (Japan)

^c Social Insurance Chuo General Hospital   (Japan)

^d Yamakawa Clinic   (Japan)

^e ASTRAZENECA   (United Kingdom)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Budesonide; Crohn's disease; Japanese patients

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUDESONIDE; MESALAZINE; PLACEBO; SALAZOSULFAPYRIDINE; SERUM ALBUMIN;

ACNE; ADULT; ANEMIA; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CROHN DISEASE; CUSHING SYNDROME; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; HYPOCALCEMIA; INCREASED APPETITE; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; JAPANESE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MELENA; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARALLEL DESIGN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CROHN DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873709770     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.06.006     Document Type: Article

References (32)

1. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369(9573):1641-1657.
2. Yao T., Matsui T., Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000, 43(10 Suppl.):S85-S93.
3. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369(9573):1627-1640.
4. Asakura K., Nishiwaki Y., Inoue N., Hibi T., Watanabe M., Takebayashi T. Prevalence of ulcerative colitis and Crohn's disease in Japan. J Gastroenterol 2009, 44(7):659-665.
5. Iida M., Yao T., Okada M. Long-term follow-up study of Crohn's disease in Japan. The Research Committee of Inflammatory Bowel Disease in Japan. J Gastroenterol 1995, 30(Suppl. 8):17-19.
6. Oriuchi T., Hiwatashi N., Kinouchi Y., Takahashi S., Takagi S., Negoro K., et al. Clinical course and longterm prognosis of Japanese patients with Crohn's disease: predictive factors, rates of operation, and mortality. J Gastroenterol 2003, 38(10):942-953.
7. Uno H., Yao T., Matsui T., Sakurai T., Iida M., Matsumoto T., et al. Mortality and cause of death in Japanese patients with Crohn's disease. Dis Colon Rectum 2003, 46(10 Suppl.):S15-S21.
8. Matsui T., Sakurai T., Yao T. Nutritional therapy for Crohn's disease in Japan. J Gastroenterol 2005, 40(Suppl. 16):25-31.
9. Rutgeerts P., Lofberg R., Malchow H., Lamers C., Olaison G., Jewell D., et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994, 331(13):842-845.
10. Campieri M., Ferguson A., Doe W., Persson T., Nilsson L.G. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997, 41(2):209-214.
11. Thomsen O.O., Cortot A., Jewell D., Wright J.P., Winter T., Veloso F.T., et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 1998, 339(6):370-374.
12. McKeage K., Goa K.L. Budesonide (Entocort EC capsules): a review of its therapeutic use in the management of active Crohn's disease in adults. Drugs 2002, 62(15):2263-2282.
13. Hofer K.N. Oral budesonide in the management of Crohn's disease. Ann Pharmacother 2003, 37(10):1457-1464.
14. Tromm A., Bunganic I., Tomsova E., Tulassay Z., Lukas M., Kykal J., et al. Budesonide 9mg is at least as effective as mesalamine 4.5g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011, 140(2):425-434.
15. Lichtenstein G.R., Hanauer S.B., Sandborn W.J. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104(2):465-483.
16. Best W.R., Becktel J.M., Singleton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70(3):439-444.
17. Hashimoto H., Green J., Iwao Y., Sakurai T., Hibi T., Fukuhara S. Reliability, validity, and responsiveness of the Japanese version of the Inflammatory Bowel Disease Questionnaire. J Gastroenterol 2003, 38(12):1138-1143.
18. Newcombe R.G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998, 17(8):873-890.
19. Greenberg G.R., Feagan B.G., Martin F., Sutherland L.R., Thomson A.B., Williams C.N., et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 1994, 331(13):836-841.
20. Tremaine W.J., Hanauer S.B., Katz S., Winston B.D., Levine J.G., Persson T., et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002, 97(7):1748-1754.
21. AstraZeneca Entocort EC (budesonide) capsules: prescribing information Available from. http://www.entocortec.com/PDF/ENTOCORT_PI.pdf.
22. Asakura H., Yao T., Matsui T., Koganei K., Fukushima T., Takazoe M., et al. Efficacy of treatment with chimeric monoclonal antibody (infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J Gastroenterol Hepatol 2001, 16(7):763-769.
23. Matsumoto T., Iida M., Motoya S., Haruma K., Suzuki Y., Kobayashi K., et al. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey. Dis Colon Rectum 2008, 51(6):916-923.
24. Inoue S., Nakase H., Matsuura M., Ueno S., Uza N., Kitamura H., et al. Open label trial of clarithromycin therapy in Japanese patients with Crohn's disease. J Gastroenterol Hepatol 2007, 22(7):984-988.
25. Ishikawa T., Okamura S., Oshimoto H., Kobayashi R., Mori M. Metronidazole plus ciprofloxacin therapy for active Crohn's disease. Intern Med 2003, 42(4):318-321.
26. Feagan B.G., Greenberg G.R., Wild G., Fedorak R.N., Pare P., McDonald J.W., et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008, 6(12):1370-1377.
27. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132(1):52-65.
28. Irvine E.J., Greenberg G.R., Feagan B.G., Martin F., Sutherland L.R., Thomson A.B., et al. Quality of life rapidly improves with budesonide therapy for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. Inflamm Bowel Dis 2000, 6(3):181-187.
29. Tursi A., Giorgetti G.M., Brandimarte G., Elisei W., Aiello F. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study. Med Sci Monit 2006, 12(6):PI29-PI32.
30. Thomsen O.O., Cortot A., Jewell D., Wright J.P., Winter T., Veloso F.T., et al. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life. Am J Gastroenterol 2002, 97(3):649-653.
31. Seow C.H., Benchimol E.I., Griffiths A.M., Otley A.R., Steinhart A.H. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008, (3):CD000296.
32. Edsbacker S., Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet 2004, 43(12):803-821.